Rat liver catechol-O-methyltransferase kinetics and assay methodology

被引:5
作者
Borges, N [1 ]
Vieira-Coelho, MA [1 ]
Parada, A [1 ]
Soares-da-Silva, P [1 ]
机构
[1] BIAL, Dept Res & Dev, P-4785 S Mamede Do Coronado, Portugal
来源
JOURNAL OF ENZYME INHIBITION | 1998年 / 13卷 / 06期
关键词
catechbol-O-methyltransferase; liver; adrenaline; metanephrine;
D O I
10.3109/14756369809020551
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In mammals, catechol-O-methyltransferase (COMT) is distributed throughout various organs, the highest activities being found in the liver and kidney. However, comparisons of the kinetic parameters are difficult to perform, since the experimental procedures in the enzyme assay vary quite considerably. The present work was aimed at studying the optimal liver COMT assay conditions for determining the kinetics of the enzyme. The COMT assay was performed with liver homogenates from 60 days old male Wistar rats with adrenaline (AD) as the substrate. Time course experiments using 100 mu M S-adenosyl-L-methionine (SAMe) and 300 mu M AD showed linearity of O-melhylation reaction upto 10 min. Using 100 mu M SAMe, V-max (nmol mg protein(-1) h(-1)) and K-m (mu M) values progressively decreased respectively from 22.1 and 104.8 at 5 min down to 5.8 and 24.62 at 60 min incubation periods. This decrease was not due to end-product inhibition, Using 2500 mu M AD, K-m values (mu M) for the methyl donor SAMe increased progressively from 174 at 5 min upto 1192.5 at 60 min; upto 30 min of incubation V-max values did not change. When a 5 min incubation period and 500 mu M SAMe were used, V-max K-m values for liver COIMT were 63.4 nmol mg protein(-1) h(-1) and 261.1 mu M, respectively. It is concluded that an incubation period of 5 min and a SAMe concentration of 500 mu M provide optimal conditions for the liver homogenate COMT assay.
引用
收藏
页码:473 / 483
页数:11
相关论文
共 29 条
[1]  
AXELROD J, 1958, J BIOL CHEM, V233, P702
[2]   PURIFICATION AND KINETIC-PROPERTIES OF LIVER MICROSOMAL-CATECHOL-O-METHYLTRANSFERASE [J].
BORCHARDT, RT ;
CHENG, CF ;
COOKE, PH ;
CREVELING, CR .
LIFE SCIENCES, 1974, 14 (06) :1089-1100
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   EFFECTS OF TOLCAPONE IN PARKINSONS PATIENTS TAKING L-DIHYDROXYPHENYLALANINE/CARBIDOPA AND SELEGILINE [J].
DAVIS, TL ;
ROZNOSKI, M ;
BURNS, RS .
MOVEMENT DISORDERS, 1995, 10 (03) :349-351
[5]  
DEGUCHI T, 1971, J BIOL CHEM, V246, P3175
[6]  
GULDBERG HC, 1975, PHARMACOL REV, V27, P135
[7]   ROLE OF ASCORBATE IN PROTECTION BY NITECAPONE AGAINST CARDIAC ISCHEMIA-REPERFUSION INJURY [J].
HARAMAKI, N ;
STEWART, DB ;
AGGARWAL, S ;
KAWABATA, T ;
PACKER, L .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (06) :839-843
[8]   CHARACTERIZATION OF MEMBRANE-BOUND AND SOLUBLE CATECHOL-O-METHYLTRANSFERASE FROM HUMAN FRONTAL-CORTEX [J].
JEFFERY, DR ;
ROTH, JA .
JOURNAL OF NEUROCHEMISTRY, 1984, 42 (03) :826-832
[9]   GENERAL-PROPERTIES AND CLINICAL POSSIBILITIES OF NEW SELECTIVE INHIBITORS OF CATECHOL O-METHYLTRANSFERASE [J].
KAAKKOLA, S ;
GORDIN, A ;
MANNISTO, PT .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1994, 25 (05) :813-824
[10]  
KOPIN IJ, 1985, PHARMACOL REV, V37, P333